{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:00:11Z","timestamp":1792652411190,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T00:00:00Z","timestamp":1589760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T00:00:00Z","timestamp":1589760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There are concerns that effectiveness and consistency of biopharmaceutical formulations, including vaccines, may be compromised by differences in size, concentration and shape of particles in suspension. Thus, a simple method that can help monitor and characterize these features is needed. Here, nanoparticle tracking analysis (NTA) was used to characterize particle concentration and size distribution of a highly-purified rabies vaccine (RABV), produced in Vero cells without raw materials of animal origin (RMAO). The NTA technique was qualified for characterization of RABV particles by assessing the stability profile of vaccine particles over 5\u201355\u2009\u00b0C. Antigenicity of the viral particle was also monitored with the enzyme-linked immunosorbent assay (ELISA) and NTA. RABV particle size diameters were 100\u2013250\u2009nm (mean:150\u2009nm), similar to sizes obtained when labelled with rabies anti-G D1\u201325 monoclonal antibody, suggesting mainly antigenic virus-like particles, also confirmed by transmission electron microscopy. Thermal stress at 55\u2009\u00b0C decreased the concentration of anti-G D1\u201325-labelled particles from 144\u2009hours, coherent with conformational changes leading to loss of G protein antigenicity without impacting aggregation. Results from RABV antigenicity assessment during the 24 months monitoring of stability showed good correlation between NTA and ELISA. NTA is a suitable approach for the characterization of biopharmaceutical suspensions.<\/jats:p>","DOI":"10.1038\/s41598-020-64572-6","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T10:02:50Z","timestamp":1589796170000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Rabies Vaccine Characterization by Nanoparticle Tracking Analysis"],"prefix":"10.1038","volume":"10","author":[{"given":"M. E.","family":"Navarro Sanchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Soulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Guinchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Nougarede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,18]]},"reference":[{"key":"64572_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-016-0540-y","volume":"18","author":"AC Jackson","year":"2016","unstructured":"Jackson, A. C. Human Rabies: a 2016 Update. Curr. Infect. Dis. Rep. 18, 38, https:\/\/doi.org\/10.1007\/s11908-016-0540-y (2016).","journal-title":"Curr. Infect. Dis. Rep."},{"key":"64572_CR2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.vaccine.2010.08.082","volume":"93","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Rabies vaccines: WHO position paper \u2013 April 2018. Wkly. Epidemiol. Rec. 93, 201\u2013220, https:\/\/doi.org\/10.1016\/j.vaccine.2010.08.082 (2018).","journal-title":"Wkly. Epidemiol. Rec."},{"key":"64572_CR3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1136\/bmj.1.1319.671","volume":"1","author":"MW Vignal","year":"1886","unstructured":"Vignal, M. W. Report on M, Pasteur\u2019s Researches on Rabies and the Treatment of Hydrophobia by Preventive Inoculation. Br. Med. J. 1, 671\u2013673 (1886).","journal-title":"Br. Med. J."},{"key":"64572_CR4","doi-asserted-by":"publisher","first-page":"12273","DOI":"10.1073\/pnas.1414226111","volume":"111","author":"R. R. Inner Workings","year":"2014","unstructured":"R. R. Inner Workings. 1885, the first rabies vaccination in humans. Proc. Natl Acad. Sci. USA 111, 12273 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"64572_CR5","first-page":"765","volume":"101","author":"L Pasteur","year":"1885","unstructured":"Pasteur, L. M\u00e9thode pour pr\u00e9venir la rage apr\u00e8s morsure. C. R. Acad. Sci. 101, 765\u2013774 (1885).","journal-title":"C. R. Acad. Sci."},{"key":"64572_CR6","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1586\/erv.11.140","volume":"10","author":"X Wu","year":"2011","unstructured":"Wu, X., Smith, T. G. & Rupprecht, C. E. From brain passage to cell adaptation: the road of human rabies vaccine development. Expert. Rev. Vaccines 10, 1597\u20131608, https:\/\/doi.org\/10.1586\/erv.11.140 (2011).","journal-title":"Expert. Rev. Vaccines"},{"key":"64572_CR7","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1002\/jps.23243","volume":"101","author":"E Marszal","year":"2012","unstructured":"Marszal, E. & Fowler, E. Workshop on predictive science of the immunogenicity aspects of particles in biopharmaceutical products. J. Pharm. Sci. 101, 3555\u20133559, https:\/\/doi.org\/10.1002\/jps.23243 (2012).","journal-title":"J. Pharm. Sci."},{"key":"64572_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3109\/1547691X.2013.821564","volume":"11","author":"KD Ratanji","year":"2014","unstructured":"Ratanji, K. D., Derrick, J. P., Dearman, R. J. & Kimber, I. Immunogenicity of therapeutic proteins: Influence of aggregation. J. Immunotoxicol. 11, 99\u2013109, https:\/\/doi.org\/10.3109\/1547691X.2013.821564 (2014).","journal-title":"J. Immunotoxicol."},{"key":"64572_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2012.04.040","volume":"431","author":"W Wang","year":"2012","unstructured":"Wang, W. et al. Immunogenicity of protein aggregates\u2014Concerns and realities. Int. J. Pharm. 431, 1\u201311, https:\/\/doi.org\/10.1016\/j.ijpharm.2012.04.040 (2012).","journal-title":"Int. J. Pharm."},{"key":"64572_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.virol.2007.01.011","volume":"363","author":"J Denis","year":"2007","unstructured":"Denis, J. et al. Immunogenicity of papaya mosaic virus-like particles fused to a hepatitis C virus epitope: Evidence for the critical function of multimerization. Virology 363, 59\u201368, https:\/\/doi.org\/10.1016\/j.virol.2007.01.011 (2007).","journal-title":"Virology"},{"key":"64572_CR11","doi-asserted-by":"publisher","first-page":"e36996","DOI":"10.1371\/journal.pone.0036996","volume":"7","author":"F Qian","year":"2012","unstructured":"Qian, F. et al. Immunogenicity of Self-Associated Aggregates and Chemically Cross-Linked Conjugates of the 42 kDa Plasmodium falciparum Merozoite Surface Protein-1. PLoS ONE 7, e36996, https:\/\/doi.org\/10.1371\/journal.pone.0036996 (2012).","journal-title":"PLoS ONE"},{"key":"64572_CR12","doi-asserted-by":"publisher","first-page":"8475","DOI":"10.1016\/j.biomaterials.2010.07.068","volume":"31","author":"JS Rudra","year":"2010","unstructured":"Rudra, J. S., Tripathi, P. K., Hildeman, D. A., Jung, J. P. & Collier, J. H. Immune responses to coiled coil supramolecular biomaterials. Biomaterials 31, 8475\u20138483, https:\/\/doi.org\/10.1016\/j.biomaterials.2010.07.068 (2010).","journal-title":"Biomaterials"},{"key":"64572_CR13","unstructured":"European Directorate For The Quality Of Medicine (EDQM). Particulate contamination in Subvisible particles (Sixth Edition) Ph.Eur. 2.9.19 (EDQM Strasbourg, 2008)."},{"key":"64572_CR14","unstructured":"European Directorate For The Quality Of Medicine (EDQM). Particulate contamination in Visible particles (Sixth Edition) Ph.Eur. 2.9.20 (EDQM Strasbourg, 2008)."},{"key":"64572_CR15","unstructured":"United States Pharmacopeia and National Formulary in Particulate matter in injections. USP 788 (United States Pharmacopeia and National Formulary Rockville, MD, 2009)."},{"key":"64572_CR16","unstructured":"United States Pharmacopeia and National Formulary in Injections\/General requirements. USP35-NF30 (United States Pharmacopeia and National Formulary Rockville, MD, 2012)."},{"key":"64572_CR17","unstructured":"United States Pharmacopeia and National Formulary in Injections\/General requirements. USP 1787 (United States Pharmacopeia and National Formulary Rockville, MD, 2015)."},{"key":"64572_CR18","unstructured":"Wright, M. Nanoparticle Tracking Analysis in Encyclopedia of Nanotechnology (ed Bharat Bhushan) 1652\u20131660 (Springer Netherlands, 2012)."},{"key":"64572_CR19","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s11095-010-0073-2","volume":"27","author":"V Filipe","year":"2010","unstructured":"Filipe, V., Hawe, A. & Jiskoot, W. Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm. Res. 27, 796\u2013810, https:\/\/doi.org\/10.1007\/s11095-010-0073-2 (2010).","journal-title":"Pharm. Res."},{"key":"64572_CR20","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/978-1-61779-953-2_41","volume":"906","author":"M Wright","year":"2012","unstructured":"Wright, M. Nanoparticle tracking analysis for the multiparameter characterization and counting of nanoparticle suspensions. Methods Mol. Biol. 906, 511\u2013524, https:\/\/doi.org\/10.1007\/978-1-61779-953-2_41 (2012).","journal-title":"Methods Mol. Biol."},{"key":"64572_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ejpb.2018.08.006","volume":"132","author":"D Clenet","year":"2018","unstructured":"Clenet, D. et al. Biophysical virus particle specific characterization to sharpen the definition of virus stability. Eur. J. Pharm. Biopharm. 132, 62\u201369, https:\/\/doi.org\/10.1016\/j.ejpb.2018.08.006 (2018).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"64572_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/1743-422x-9-265","volume":"9","author":"P Kramberger","year":"2012","unstructured":"Kramberger, P., Ciringer, M., Strancar, A. & Peterka, M. Evaluation of nanoparticle tracking analysis for total virus particle determination. Virol. J. 9, 265, https:\/\/doi.org\/10.1186\/1743-422x-9-265 (2012).","journal-title":"Virol. J."},{"key":"64572_CR23","doi-asserted-by":"publisher","first-page":"e0142415","DOI":"10.1371\/journal.pone.0142415","volume":"10","author":"N Nikitin","year":"2015","unstructured":"Nikitin, N. et al. Comparative Study of Non-Enveloped Icosahedral Viruses Size. PLoS One 10, e0142415, https:\/\/doi.org\/10.1371\/journal.pone.0142415 (2015).","journal-title":"PLoS One"},{"key":"64572_CR24","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S1773-2247(12)50069-9","volume":"22","author":"E Patois","year":"2012","unstructured":"Patois, E., Capelle, M. A. H., Palais, C., Gurny, R. & Arvinte, T. Evaluation of nanoparticle tracking analysis (NTA) in the characterization of therapeutic antibodies and seasonal influenza vaccines: Pros and cons. J. Drug. Deliv. Sci. Technol. 22, 427\u2013433 (2012).","journal-title":"J. Drug. Deliv. Sci. Technol."},{"key":"64572_CR25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.biologicals.2017.02.002","volume":"46","author":"M Chabaud-Riou","year":"2017","unstructured":"Chabaud-Riou, M. et al. G-protein based ELISA as a potency test for rabies vaccines. Biologicals 46, 124\u2013129, https:\/\/doi.org\/10.1016\/j.biologicals.2017.02.002 (2017).","journal-title":"Biologicals"},{"key":"64572_CR26","unstructured":"Rupprecht, C. E. in Medical Microbiology Vol. Chapter 61. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK8618. Last accessed April 2020 (ed Baron S) (Galveston (TX): University of Texas Medical Branch at Galveston, 1996)."},{"key":"64572_CR27","unstructured":"ICTV virus taxonomy. Genus: lyssavirus. Available at, https:\/\/talk.ictvonline.org\/ictv-reports\/ictv_online_report\/negative-sense-rna-viruses\/mononegavirales\/w\/rhabdoviridae\/795\/genus-lyssavirus. Last accessed April 2020."},{"key":"64572_CR28","doi-asserted-by":"crossref","unstructured":"Singh, K., Rupprecht, C. E. & Bleck, T. P. in Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases (Eighth Edition) Vol. 2 Ch. 165, 1984\u20131994.e1982 (Elsevier, 2015).","DOI":"10.1016\/B978-1-4557-4801-3.00165-X"},{"key":"64572_CR29","doi-asserted-by":"crossref","unstructured":"Willoughby, R. E. in Principles and Practice of Pediatric Infectious Diseases (Fourth Edition) (ed S.S. Long) Ch. 228, 1145\u20131149.e1142 (Elsevier, 2012).","DOI":"10.1016\/B978-1-4377-2702-9.00230-0"},{"key":"64572_CR30","doi-asserted-by":"publisher","first-page":"1344087","DOI":"10.1080\/20013078.2017.1344087","volume":"6","author":"B Vestad","year":"2017","unstructured":"Vestad, B. et al. Size and concentration analyses of extracellular vesicles by nanoparticle tracking analysis: a variation study. J. Extracell. Vesicles 6, 1344087, https:\/\/doi.org\/10.1080\/20013078.2017.1344087 (2017).","journal-title":"J. Extracell. Vesicles"},{"key":"64572_CR31","unstructured":"ASTM International in Standard Guide for Measurement of Particle Size Distribution of Nanomaterials in Suspension by Nanoparticle Tracking Analysis (NTA). ASTM E2834-12 (ASTM International, West Conshohocken, PA, 2012). Available at, https:\/\/www.astm.org\/DATABASE.CART\/HISTORICAL\/E2834-12.htm. Last accessed April 2020."},{"key":"64572_CR32","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.vaccine.2016.12.039","volume":"35","author":"S Morgeaux","year":"2017","unstructured":"Morgeaux, S. et al. Replacement of in vivo human rabies vaccine potency testing by in vitro glycoprotein quantification using ELISA - Results of an international collaborative study. Vaccine 35, 966\u2013971, https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.039 (2017).","journal-title":"Vaccine"}],"updated-by":[{"DOI":"10.1038\/s41598-021-82766-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64572-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64572-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64572-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T11:21:24Z","timestamp":1670325684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-64572-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,18]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["64572"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-64572-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,18]]},"assertion":[{"value":"20 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.E.N.S., D.S., E.B., F.G., S.M., E.V. and N.N. are all employees of Sanofi Pasteur.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8149"}}